TCGA-GV-A3JZ-01A-11R-A21D-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 19.80946124
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.390
- PANCREAS_BETA_CELLS+0.370
- G2M_CHECKPOINT+0.360
- MYC_TARGETS_V1+0.240
- MYC_TARGETS_V2+0.230
- SPERMATOGENESIS+0.230
- ANGIOGENESIS+0.220
- MTORC1_SIGNALING+0.220
- MITOTIC_SPINDLE+0.210
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.090
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.530
- INTERFERON_GAMMA_RESPONSE-0.460
- P53_PATHWAY-0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
- TNFA_SIGNALING_VIA_NFKB-0.360
- ALLOGRAFT_REJECTION-0.300
- INFLAMMATORY_RESPONSE-0.290
- APICAL_SURFACE-0.270
- APOPTOSIS-0.250
- IL6_JAK_STAT3_SIGNALING-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG592 | — | — | 0.884 |
| 2 | BS_AHEFXG7W | medulloblastoma | — | 0.871 |
| 3 | SRR15069603 | — | — | 0.855 |
| 4 | BS_1AYRM596 | medulloblastoma | — | 0.855 |
| 5 | BS_FKDQJJB5 | medulloblastoma | — | 0.854 |
| 6 | DRR168561 | — | — | 0.845 |
| 7 | BS_81SP2HX4 | medulloblastoma | — | 0.845 |
| 8 | SAMN03290918 | — | — | 0.845 |
| 9 | 0edf46a2-3dfb-4bae-b642-281e05975bd1 | — | — | 0.842 |
| 10 | MNG737 | — | — | 0.842 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.370 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.240 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.230 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.220 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.090 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.090 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.050 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.050 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.040 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.020 | Idelalisib | — uncovered |